Naoki Shingu
Kumamoto, 8614193, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 30, 2025
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003).
Journal: JTO clinical and research reports
Published: December 04, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 07, 2024
Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.
Journal: Clinical lung cancer
Published: February 18, 2024
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Journal: Thoracic cancer
Published: October 22, 2022
Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 27, 2021
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia.
Journal: Scientific reports
Published: March 31, 2021
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Journal: International journal of clinical oncology
Published: May 21, 2020
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Journal: Thoracic cancer
Published: July 13, 2019
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 28, 2018
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Journal: Anticancer research
Published: December 08, 2018
The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Journal: Asia-Pacific journal of clinical oncology
Published: December 28, 2017
Last Updated: 09/26/2026